CD22 and acute lymphoblastic leukemia: compared the characteristics and clinical outcomes of CD19 single-target (ChiCTR-ORN-16008948, n = 35) and CD19/CD22 bispecific-targeted (ChiCTR1800015575, n  =  15) CAR-T cells in a retrospective study of 50 patients with r/r ALL.